Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities
Identifieur interne : 002675 ( Main/Exploration ); précédent : 002674; suivant : 002676Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities
Auteurs : Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Denervation, Dopamine (physiology), Dopamine agonist, Drug Administration Schedule, Dyskinesia, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (therapeutic use), L‐dopa, MPTP, Movement Disorders (etiology), Movement Disorders (physiopathology), Movement Disorders (prevention & control), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Primates, Time Factors, continuous dopaminergic stimulation, dopamine agonists, dyskinesia, primates.
- MESH :
- chemical , administration & dosage : Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , physiology : Dopamine.
- chemical , therapeutic use : Levodopa.
- drug therapy : Parkinson Disease.
- etiology : Movement Disorders.
- physiopathology : Movement Disorders, Parkinson Disease.
- prevention & control : Movement Disorders.
- Denervation, Drug Administration Schedule, Humans, Time Factors.
Abstract
Dyskinesia affects ∼30 to 40% of patients with Parkinson's disease but treatment options for the prevention of dyskinesia induction and for the suppression of established dyskinesia are limited. This situation is made more difficult by a poor understanding of the pathphysiology of the processes underlying both the priming for dyskinesia and the manifestations of involuntary movements. Loss of tonic stimulation of striatal dopamine receptors in PD and its replacement by pulsatile dopaminergic stimulation using short acting drugs has been proposed as leading to the abnormalities that cause dyskinesia induction. As a consequence, the concept of continuous dopaminergic stimulation (CDS) was introduced to explain why longer acting dopamine agonists do not produce the same intensity of dyskinesia. Key to these ideas has been the use of both 6‐OHDA lesioned rodent models of PD and, in particular MPTP‐treated primates. Comparison of the ability to induce dyskinesia of the same dopamine agonists given by pulsatile or continuous administration or more constant administration of Levodopa (L‐dopa) has shown that constant drug delivery (CDD) dramatically reduces dyskinesia induction. Similar conclusions have been reached from clinical investigations in PD. Recent studies in MPTP‐treated primates have also suggested that switching from pulsatile drug delivery to CDD can be utilized to inhibit dyskinesia expression. However, CDS does explain some important features of dyskinesia induction in PD but it may not apply to early PD when remaining dopaminergic neurones buffer against pulsatile stimulation. In addition, CDS may not apply when comparing between drug classes and it appears that it is CDD which is more important in regulating therapeutic efficacy. Recently, studies in MPTP‐treated primates have suggested that a range of nondopaminerigic drugs might be useful in suppressing dyskinesia. These have included 5‐HT‐1A agonists and α‐2 adrenergic antagonists and a variety of other molecular entities. Unfortunately, these findings are not always reproducible in the same models and do not translate into clinically useful effects. Preclinical studies have suggested a number of directions that might be utilized to prevent dyskinesia in PD. However, much of what is proposed is empirically‐based and we still do not have a good understanding of why dyskinesia appears, why it persists or how to bring the movements under control. Certainly, the use of CDD can reduce dyskinesia intensity but other factors also influence its appearance and it is these that we need to study at the preclinical level if effective therapies are to be developed. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22022
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000195
- to stream Istex, to step Curation: 000195
- to stream Istex, to step Checkpoint: 001231
- to stream PubMed, to step Corpus: 002054
- to stream PubMed, to step Curation: 002054
- to stream PubMed, to step Checkpoint: 002126
- to stream Ncbi, to step Merge: 002309
- to stream Ncbi, to step Curation: 002309
- to stream Ncbi, to step Checkpoint: 002309
- to stream Main, to step Merge: 003253
- to stream PascalFrancis, to step Corpus: 001126
- to stream PascalFrancis, to step Curation: 001B93
- to stream PascalFrancis, to step Checkpoint: 001125
- to stream Main, to step Merge: 003733
- to stream Main, to step Curation: 002675
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities</title>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:47C0F3E4F24ACC4B4CCC8A9E3AAB03F302CF7EDC</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22022</idno>
<idno type="url">https://api.istex.fr/document/47C0F3E4F24ACC4B4CCC8A9E3AAB03F302CF7EDC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000195</idno>
<idno type="wicri:Area/Istex/Curation">000195</idno>
<idno type="wicri:Area/Istex/Checkpoint">001231</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Jenner P:preventing:and:controlling</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18781676</idno>
<idno type="wicri:Area/PubMed/Corpus">002054</idno>
<idno type="wicri:Area/PubMed/Curation">002054</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002126</idno>
<idno type="wicri:Area/Ncbi/Merge">002309</idno>
<idno type="wicri:Area/Ncbi/Curation">002309</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002309</idno>
<idno type="wicri:Area/Main/Merge">003253</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0466173</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001126</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B93</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001125</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Jenner P:preventing:and:controlling</idno>
<idno type="wicri:Area/Main/Merge">003733</idno>
<idno type="wicri:Area/Main/Curation">002675</idno>
<idno type="wicri:Area/Main/Exploration">002675</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities</title>
<author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008">2008</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="supplement">S3</biblScope>
<biblScope unit="page" from="S585">S585</biblScope>
<biblScope unit="page" to="S598">S598</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">47C0F3E4F24ACC4B4CCC8A9E3AAB03F302CF7EDC</idno>
<idno type="DOI">10.1002/mds.22022</idno>
<idno type="ArticleID">MDS22022</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Denervation</term>
<term>Dopamine (physiology)</term>
<term>Dopamine agonist</term>
<term>Drug Administration Schedule</term>
<term>Dyskinesia</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>L‐dopa</term>
<term>MPTP</term>
<term>Movement Disorders (etiology)</term>
<term>Movement Disorders (physiopathology)</term>
<term>Movement Disorders (prevention & control)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Primates</term>
<term>Time Factors</term>
<term>continuous dopaminergic stimulation</term>
<term>dopamine agonists</term>
<term>dyskinesia</term>
<term>primates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Denervation</term>
<term>Drug Administration Schedule</term>
<term>Humans</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Primates</term>
<term>Stimulant dopaminergique</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dyskinesia affects ∼30 to 40% of patients with Parkinson's disease but treatment options for the prevention of dyskinesia induction and for the suppression of established dyskinesia are limited. This situation is made more difficult by a poor understanding of the pathphysiology of the processes underlying both the priming for dyskinesia and the manifestations of involuntary movements. Loss of tonic stimulation of striatal dopamine receptors in PD and its replacement by pulsatile dopaminergic stimulation using short acting drugs has been proposed as leading to the abnormalities that cause dyskinesia induction. As a consequence, the concept of continuous dopaminergic stimulation (CDS) was introduced to explain why longer acting dopamine agonists do not produce the same intensity of dyskinesia. Key to these ideas has been the use of both 6‐OHDA lesioned rodent models of PD and, in particular MPTP‐treated primates. Comparison of the ability to induce dyskinesia of the same dopamine agonists given by pulsatile or continuous administration or more constant administration of Levodopa (L‐dopa) has shown that constant drug delivery (CDD) dramatically reduces dyskinesia induction. Similar conclusions have been reached from clinical investigations in PD. Recent studies in MPTP‐treated primates have also suggested that switching from pulsatile drug delivery to CDD can be utilized to inhibit dyskinesia expression. However, CDS does explain some important features of dyskinesia induction in PD but it may not apply to early PD when remaining dopaminergic neurones buffer against pulsatile stimulation. In addition, CDS may not apply when comparing between drug classes and it appears that it is CDD which is more important in regulating therapeutic efficacy. Recently, studies in MPTP‐treated primates have suggested that a range of nondopaminerigic drugs might be useful in suppressing dyskinesia. These have included 5‐HT‐1A agonists and α‐2 adrenergic antagonists and a variety of other molecular entities. Unfortunately, these findings are not always reproducible in the same models and do not translate into clinically useful effects. Preclinical studies have suggested a number of directions that might be utilized to prevent dyskinesia in PD. However, much of what is proposed is empirically‐based and we still do not have a good understanding of why dyskinesia appears, why it persists or how to bring the movements under control. Certainly, the use of CDD can reduce dyskinesia intensity but other factors also influence its appearance and it is these that we need to study at the preclinical level if effective therapies are to be developed. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002675 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002675 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:47C0F3E4F24ACC4B4CCC8A9E3AAB03F302CF7EDC |texte= Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |